Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Raulet
University of California Berkeley, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aduro Biotech
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Conflict of Interest Committee determined that the PI’s interest in Aduro Biotech, is related to the interest of the project and represents an FCOI in that those interests could directly and significantly affect the design, conduct or reporting of the PHS-funded research because knowledge gained in the course of the project may contribute to the cardiac chip being developed by the Investigator at the entity.
STING-dependent activation of Natural Killer cells by viral and tumor DNA
Recognition of cytosolic DNA is an important mechanism by which innate immune responses to viruses and tumors are initiated. We expect that developing a better understanding of how recognition of foreign and self DNA leads to immune activation will allow the development of improved immunotherapeutics and vaccines.
Filed on February 16, 2017.
Tell us what you know about David Raulet's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Raulet filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Raulet | University of California Berkeley | Conflict of Interest | Innate Pharma | $60,000 - $79,999 |
| David Raulet | University of California Berkeley | Conflict of Interest | Aduro Biotech | $10,000 - $19,999 |
Other search results for: “David Raulet”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Raulet | University of California Berkeley | Financial Disclosure | Dragonfly Therapeutics | |
| David Raulet | University of California Berkeley | Financial Disclosure | Aduro Biotech | |
| David Raulet | University of California Berkeley | Financial Disclosure | Aduro Biotech |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.